Cardiol Therapeutics Inc. (CRDL) Form 6-K — Sep 16, 2026
Cardiol Therapeutics announced on September 16, 2026 that it has received over USD $7 million in proceeds from the exercise of outstanding common share purchase warrants originally issued in an October 2025 private placement of units. The capital extends the company's cash runway into H1 2028, funding operations through the topline data readout of the pivotal Phase III MAVERIC trial of CardiolRx in recurrent pericarditis, supporting regulatory preparations for a potential New Drug Application, and advancing the broader pipeline including the subcutaneous CRD-38 program.
Key figures
- Gross Proceeds
- over USD $7 million
- Cash runway
- into H1 2028
- Early expiry date
- October 16, 2026
- Warrants originally issued
- 5712500
- Acceleration right exercised
- Yes
- Warrants remaining unexercised
- 425000
- Remaining potential gross proceeds usd
- 573750
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.